Current analyst assessments
On this page you will find current analyst assessments of renowned research houses, which make their assessments on the business development of listed companies available for publication and distribution via our content partner EQS-Newswire.
This might be interesting for you as well
Source:
-
13 November 2023 10:05AM
More to come in RNAi therapy discovery
London, UK, 13 November 2023
Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
e-therapeutics reported H1 FY24 results (to end-July 2023), reaffirming its commitment to integrating its computational and hepatocyte biology expertise to develop short interfering RNA (siRNA) therapies. The key half-year devel...
Edison Investment Research Limited
Info
The information presented here was provided by our content partner EQS. The assessments of the analyst houses were transmitted in the original via the news service EQS-Newswire for publication via the affiliated distribution networks.
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.